Literature DB >> 21427065

Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.

A M Vandone1, M Donadio2, M Mozzati3, M Ardine2, M A Polimeni2, S Beatrice2, L Ciuffreda2, M Scoletta3.   

Abstract

BACKGROUND: Osteonecrosis of the jaw (ONJ) is associated with bisphosphonate (BP) therapy and invasive dental care. An Interdisciplinary Care Group (ICG) was created to evaluate dental risk factors and the efficacy of a preventive restorative dental care in the reduction of ONJ risk. PATIENTS AND METHODS: This prospective single-center study included patients with bone metastases from solid tumors. Patients who received at least one BP infusion between October 2005 and 31 August 2009 underwent one or more ICG evaluation and regular dental examinations. We also retrospectively evaluated patients with bone metastases from solid tumors who did not undergo dental preventive measures.
RESULTS: Of 269 patients, 211 had received at least one infusion of BP therapy: 62% were BP naive and 38% had previous BP exposure. Of these 211 patients followed for 47 months, 6 patients developed ONJ (2.8%). Of 200 patients included in the retrospective analysis, 11 patients developed ONJ (5.5%).
CONCLUSIONS: In comparison with published ONJ rates and those extrapolated from the retrospective analysis, the observed ONJ rate in the prospective group was lower, suggesting that implementation of a preventive dental program may reduce the risk of ONJ in metastatic patients treated with i.v. BP therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427065     DOI: 10.1093/annonc/mdr039

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  38 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw.

Authors:  Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez
Journal:  Support Care Cancer       Date:  2015-03-11       Impact factor: 3.603

4.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

5.  A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians.

Authors:  Sung Ok Hong; Chae-Yoon Lee; Junho Jung; Deog-Yoon Kim; Christian Walter; Yong-Dae Kwon
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

6.  Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.

Authors:  Boon Hui Chan; Ruixiang Yee; Rukshini Puvanendran; Seng Bin Ang
Journal:  Singapore Med J       Date:  2018-02       Impact factor: 1.858

7.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

8.  Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.

Authors:  Marco Mozzati; Germana Martinasso; Marina Maggiora; Matteo Scoletta; Marta Zambelli; Stefano Carossa; Manuela Oraldi; Giuliana Muzio; Rosa Angela Canuto
Journal:  Clin Oral Investig       Date:  2012-08-03       Impact factor: 3.573

9.  Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.

Authors:  Danny Hadaya; Akrivoula Soundia; Earl Freymiller; Tristan Grogan; David Elashoff; Sotirios Tetradis; Tara L Aghaloo
Journal:  J Oral Maxillofac Surg       Date:  2018-05-29       Impact factor: 1.895

10.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.

Authors:  Giacomo Oteri; Gianluca Trifirò; Matteo Peditto; Loredana Lo Presti; Ilaria Marcianò; Francesco Giorgianni; Janet Sultana; Antonia Marcianò
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.